Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group

Laurie H. Sehn; David MacDonald; Sheldon Rubin; Guy Cantin; Morel Rubinger; Bernard Lemieux; Sanraj Basi; Kevin Imrie; Randy D. Gascoyne; Jonathan Sussman; Bingshu E. Chen; Marina Djurfeldt; Lois Shepherd; Stephen Couban; Michael Crump

doi:10.1200/JCO.2010.33.6594

Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group

Laurie H. Sehn, David MacDonald, Sheldon Rubin, Guy Cantin, Morel Rubinger, Bernard Lemieux, Sanraj Basi, Kevin Imrie, Randy D. Gascoyne, Jonathan Sussman, Bingshu E. Chen, Marina Djurfeldt, Lois Shepherd, Stephen Couban, Michael Crump

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Original language	English
Pages (from-to)	3396-3401
Number of pages	6
Journal	Journal of Clinical Oncology
Volume	29
Issue number	25
DOIs	https://doi.org/10.1200/JCO.2010.33.6594
Publication status	Published - Sept 1 2011
Externally published	Yes

ASJC Scopus Subject Areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2010.33.6594

Cite this

Sehn, L. H., MacDonald, D., Rubin, S., Cantin, G., Rubinger, M., Lemieux, B., Basi, S., Imrie, K., Gascoyne, R. D., Sussman, J., Chen, B. E., Djurfeldt, M., Shepherd, L., Couban, S., & Crump, M. (2011). Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group. Journal of Clinical Oncology, 29(25), 3396-3401. https://doi.org/10.1200/JCO.2010.33.6594

Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group. / Sehn, Laurie H.; MacDonald, David; Rubin, Sheldon et al.
In: Journal of Clinical Oncology, Vol. 29, No. 25, 01.09.2011, p. 3396-3401.

Research output: Contribution to journal › Article › peer-review

Sehn, LH, MacDonald, D, Rubin, S, Cantin, G, Rubinger, M, Lemieux, B, Basi, S, Imrie, K, Gascoyne, RD, Sussman, J, Chen, BE, Djurfeldt, M, Shepherd, L, Couban, S & Crump, M 2011, 'Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group', Journal of Clinical Oncology, vol. 29, no. 25, pp. 3396-3401. https://doi.org/10.1200/JCO.2010.33.6594

@article{7ad503bfb3ce40cab114bba4ae507482,

title = "Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group",

author = "Sehn, {Laurie H.} and David MacDonald and Sheldon Rubin and Guy Cantin and Morel Rubinger and Bernard Lemieux and Sanraj Basi and Kevin Imrie and Gascoyne, {Randy D.} and Jonathan Sussman and Chen, {Bingshu E.} and Marina Djurfeldt and Lois Shepherd and Stephen Couban and Michael Crump",

year = "2011",

month = sep,

day = "1",

doi = "10.1200/JCO.2010.33.6594",

language = "English",

volume = "29",

pages = "3396--3401",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "25",

}

TY - JOUR

T1 - Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma

T2 - A phase II study by the National Cancer Institute of Canada clinical trials group

AU - Sehn, Laurie H.

AU - MacDonald, David

AU - Rubin, Sheldon

AU - Cantin, Guy

AU - Rubinger, Morel

AU - Lemieux, Bernard

AU - Basi, Sanraj

AU - Imrie, Kevin

AU - Gascoyne, Randy D.

AU - Sussman, Jonathan

AU - Chen, Bingshu E.

AU - Djurfeldt, Marina

AU - Shepherd, Lois

AU - Couban, Stephen

AU - Crump, Michael

PY - 2011/9/1

Y1 - 2011/9/1

UR - http://www.scopus.com/inward/record.url?scp=80052739391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052739391&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.6594

DO - 10.1200/JCO.2010.33.6594

M3 - Article

C2 - 21810681

AN - SCOPUS:80052739391

SN - 0732-183X

VL - 29

SP - 3396

EP - 3401

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 25

ER -

Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this